Stay updated with breaking news from Primary Endpoint. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fourth-Quarter 2022 Results: -- Net Sales of $942.0 Million -- -- GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses
01.03.2023 - - Achieved $31.3 Million in Net Revenue from Sales of COSELA (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million - - Announced Top Line Results from Pivotal Phase 3 ...
—CM-101 Met Primary Endpoint of Safety and Tolerability and Showed Positive Activity Across Multiple Liver Fibrosis Biomarkers and Physiologic Assessments— TEL AVIV, Israel, Jan. 3, 2023... | January 3, 2023
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy) - read this article along with other careers information, tips and advice on BioSpace
BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a...